Developed through innovative in vitro and in vivo models, AD-RESYL® restores homeostasis in atopic skin, by targeting its four main anomalies:
Its clinical efficacy was demonstrated under dermatological supervision (assessment of severity of symptoms: SCORAD, overall evaluation) with two cohorts of Caucasian and Asian children and/or adults affected by the disease. In addition, the patients (or their parents, in case of children) also self-evaluated their quality of life, the efficacy of the treatment and expressed their overall assessment . The SCORAD and relapse rates were significantly reduced. The treatment soothed, hydrated and comforted the skin. The quality of life of the patients and their families was considerably improved.
SILAB Softcare conducted cutaneous tolerance and risk assessment studies of its product, in compliance with the most stringent pharmaceutical standards. AD-RESYL® is perfectly tolerated by the atopic skin of Caucasian and Asian children and adults.
In addition, SILAB invested in a spray-drying production unit, also qualified according to the criteria of pharmaceutical GMP, to manufacture products in preservative-free powder, such as AD-RESYL®.